Published in J Clin Invest on May 01, 1977
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci. Infect Immun (1978) 2.15
Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med (1979) 2.06
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
Group B, type III streptococcal cell wall: composition and structural aspects revealed through endo-N-acetylmuramidase-catalyzed hydrolysis. Infect Immun (1982) 1.52
Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. J Clin Invest (1982) 1.47
Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis. Infect Immun (1990) 1.25
Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect Immun (1981) 1.22
Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease. Infect Immun (1984) 1.20
Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci. J Clin Microbiol (1978) 1.18
Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun (1999) 1.15
Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. J Clin Invest (1983) 1.15
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun (2002) 1.08
Enzyme-linked immunosorbent assay for group B streptococcal antibodies. Infect Immun (1980) 0.99
Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun (2002) 0.99
Role of C5a-ase in group B streptococcal resistance to opsonophagocytic killing. Infect Immun (1995) 0.98
Immunospecificity and quantitation of an enzyme-linked immunosorbent assay for group B streptococcal antibody. J Clin Microbiol (1982) 0.98
Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay. Infect Immun (1984) 0.94
Bactericidal capacity of newborn phagocytes against group B beta-hemolytic streptococci. Infect Immun (1981) 0.93
Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis (2013) 0.92
Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons. Infect Immun (1996) 0.91
Group B streptococcal infection: a review and update. Br J Vener Dis (1979) 0.90
Isolation, chemical composition, and molecular size of extracellular type II and type Ia polysaccharides of group B streptococci. Infect Immun (1983) 0.88
Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine (2012) 0.86
Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus. Infect Immun (1983) 0.85
Effects of route and time of administration of antiserum on protection of mice from lethal infection due to group B Streptococcus type III. Infect Immun (1981) 0.84
Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci. Infect Immun (1984) 0.83
Group B streptococcal long-chain reaction. Infect Immun (1977) 0.83
Maternal immunity and antibody response of neonatal mice to pneumococcal type 19F polysaccharide. J Clin Microbiol (1991) 0.83
Measurement of human antibodies to type III group B Streptococcus. Infect Immun (1999) 0.76
Demonstration of circulating group B streptococcal immune complexes in neonates with meningitis. J Clin Microbiol (1994) 0.75
Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections. Infection (1985) 0.75
A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J Infect Dis (1959) 22.10
Group B streptococcal neonatal and infant infections. J Pediatr (1973) 10.25
Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med (1969) 9.01
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Distribution by serological type of group B streptococci isolated from a variety of clinical material over a five-year period (with special reference to neonatal sepsis and meningitis). Infect Immun (1973) 7.01
Transmission of group B streptococci among parturient women and their neonates. J Pediatr (1973) 6.86
Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr (1973) 6.29
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) (1966) 4.55
Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol (1973) 4.49
Group B streptococcal infections in infants. The importance of the various serotypes. JAMA (1974) 3.71
Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics (1973) 3.33
Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest (1972) 3.13
Destruction of some agglutinins but not of others by two sulfhydryl compounds. Acta Pathol Microbiol Scand (1958) 3.01
Type-specific polysaccharide antigens of group B streptococci. II. The chemical basis for serological specificity of the type II HCl antigen. J Exp Med (1967) 2.92
Immunochemistry of purified polysaccharide type antigens of group B streptococcal types Ia, Ib, and Ic. Infect Immun (1975) 2.83
The effect of variation in molecular weight on the antigenicity of dextran in man. Arch Biochem Biophys (1958) 2.60
Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med (1976) 2.55
Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun (1976) 2.38
A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ (1973) 2.29
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Immunogenicity of the group A and group C meningococcal polysaccharides in children. J Infect Dis (1972) 1.81
Nosocomial transmission of group B streptococci. Pediatrics (1976) 1.62
Immunologic responses to Hemophilus influenzae meningitis. J Pediatr (1972) 1.53
Identification of sialic acid in polysaccharide antigens in group B Streptococcus. Infect Immun (1976) 1.38
Host factors and antibody response Haemophilus influenza type b meningitis and epiglottitis. J Infect Dis (1976) 1.20
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Transmission of group B streptococci among parturient women and their neonates. J Pediatr (1973) 6.86
Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr (1973) 6.29
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol (1973) 4.49
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Selective broth medium for isolation of group B streptococci. Appl Microbiol (1973) 4.42
Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr (1981) 4.00
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
Diagnosis of Chlamydia trachomatis urethral infection in symptomatic and asymptomatic men by testing first-void urine in a ligase chain reaction assay. J Infect Dis (1994) 3.93
Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81
Group B streptococcal infections in infants. The importance of the various serotypes. JAMA (1974) 3.71
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Typing of group B streptococci: comparison of pulsed-field gel electrophoresis and conventional electrophoresis. J Clin Microbiol (1993) 3.52
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis (1981) 3.30
Fifteen-month follow-up study of women infected with Chlamydia trachomatis. N Engl J Med (1979) 3.26
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen. Rev Infect Dis (1983) 3.23
The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J Infect Dis (1976) 3.20
Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol (1984) 3.15
Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med (1988) 3.14
The genital mycoplasmas (first of two parts). N Engl J Med (1980) 3.12
Active oxygen in plant pathogenesis. Annu Rev Phytopathol (1995) 3.02
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest (1990) 2.96
Bacteroides fragilis subspecies in clinical isolates. Ann Intern Med (1977) 2.95
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature (1987) 2.90
Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med (1984) 2.89
Structural features of polysaccharides that induce intra-abdominal abscesses. Science (1993) 2.86
Molecular cloning of a Pseudomonas syringae pv. syringae gene cluster that enables Pseudomonas fluorescens to elicit the hypersensitive response in tobacco plants. J Bacteriol (1988) 2.84
Nonculture tests for genital tract chlamydial infection. What does the package insert mean, and will it mean the same thing tomorrow? Sex Transm Dis (1992) 2.80
Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature (2001) 2.79
Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ (1969) 2.77
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA (1995) 2.71
Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci U S A (1992) 2.65
Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med (1976) 2.55
Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis (1999) 2.50
Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J Infect Dis (1973) 2.47
Involvement of plasma membrane calcium influx in bacterial induction of the k/h and hypersensitive responses in tobacco. Plant Physiol (1990) 2.46
Characterization of gonococcal antigens responsible for induction of bactericidal antibody in disseminated infection. J Clin Invest (1977) 2.46
Neonatal sepsis caused by a new group B streptococcal serotype. J Pediatr (1993) 2.45
Chemical and biological characterization of the lipopolysaccharide of Bacteroides fragilis subspecies fragilis. J Infect Dis (1976) 2.45
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. Development (1993) 2.41
Immunochemical characterization of the outer membrane complex of Bacteroides fragilis subspecies fragilis. J Infect Dis (1975) 2.39
Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun (1976) 2.38
Comparison of the Syva MicroTrak enzyme immunoassay and Gen-Probe PACE 2 with cell culture for diagnosis of cervical Chlamydia trachomatis infection in a high-prevalence female population. J Clin Microbiol (1993) 2.35
Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem (1987) 2.35
Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A (1996) 2.34
A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med (1991) 2.30
Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem (2001) 2.30
In whose best interest? Breaching the academic-industrial wall. N Engl J Med (2000) 2.28
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1993) 2.26
Vaginal colonization with Corynebacterium vaginale (Haemophilus vaginalis). J Infect Dis (1977) 2.23
Prolonged pneumococcal meningitis due to an organism with increased resistance to penicillin. Pediatrics (1976) 2.22
The genital mycoplasmas. N Engl J Med (1973) 2.21
Sexual behavior of college women in 1975, 1986, and 1989. N Engl J Med (1990) 2.18
Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry (1981) 2.17
Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci. Infect Immun (1978) 2.15
Comparison of bacteriological methods for the isolation of group of B Streptococcus from vaginal cultures. J Clin Microbiol (1976) 2.14
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A (1989) 2.13
Changing epidemiology of group B streptococcal colonization. Pediatrics (1999) 2.09
A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect Immun (1991) 2.06
Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med (1979) 2.06
Endemic cholera in rural East Pakistan. Am J Epidemiol (1969) 2.06
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
Enzyme immunoassay for diagnosis of gonorrhea. J Clin Microbiol (1984) 2.03
A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol (2010) 2.02
Association of Streptococcus bovis bacteremia with bowel disease. J Clin Microbiol (1983) 2.01
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. I. Study design and results of the first year of observation. Bull World Health Organ (1969) 2.00
The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem (1992) 2.00
Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother (1998) 2.00
Microbiology of the vagina in children: normal and potentially pathogenic organisms. Pediatrics (1978) 1.98
Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry (1992) 1.98
Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun (1991) 1.97
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infect Immun (1991) 1.95
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
The changing spectrum of group B streptococcal disease. N Engl J Med (1993) 1.94
Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest (1995) 1.91
Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. J Clin Microbiol (1989) 1.87
The genital mycoplasmas (second of two parts). N Engl J Med (1980) 1.86
Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics (1981) 1.83